Peripheral Sensitization Increases Opioid Receptor Expression and Activation by Crotalphine in Rats

Vanessa Olzon Zambelli¹, Ana Carolina de Oliveira Fernandes¹, Vanessa Pacciari Gutierrez¹, Julio Cesar Batista Ferreira², Carlos Amilcar Parada³, Daria Mochly-Rosen⁴, Yara Cury¹*

¹Laboratório Especial de Dor e Sinalização, Instituto Butantan, São Paulo, SP, Brazil, ²Departamento de Anatomia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil, ³Departamento de Fisiologia e Biofísica, Instituto de Biociências (UNICAMP) Rua Monteiro Lobato, Cidade Universitária, Campinas, SP, Brazil, ⁴Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, California, United States of America

Abstract

Inflammation enhances the peripheral analgesic efficacy of opioid drugs, but the mechanisms involved in this phenomenon have not been fully elucidated. Crotalphine (CRP), a peptide that was first isolated from South American rattlesnake C. d. terrificus venom, induces a potent and long-lasting anti-nociceptive effect that is mediated by the activation of peripheral opioid receptors. Because the high efficacy of CRP is only observed in the presence of inflammation, we aimed to elucidate the mechanisms involved in the CRP anti-nociceptive effect induced by inflammation. Using real-time RT-PCR, western blot analysis and ELISA assays, we demonstrate that the intraplantar injection of prostaglandin E2 (PGE2) increases the mRNA and protein levels of the µ- and κ-opioid receptors in the dorsal root ganglia (DRG) and paw tissue of rats within 3 h of the injection. Using conformation state-sensitive antibodies that recognize activated opioid receptors, we show that PGE2 alone does not increase the activation of these opioid receptors but that in the presence of PGE2 the activation of specific opioid receptors by CRP and selective µ- and κ-opioid receptor agonists (positive controls) increases. Furthermore, PGE2 down-regulated the expression and activation of the δ-opioid receptor. CRP increased the level of activated mitogen-activated protein kinases in cultured DRG neurons, and this increase was dependent on the activation of protein kinase C. This CRP effect was much more prominent when the cells were pretreated with PGE2. These results indicate that the expression and activation of peripheral opioid receptors by opioid-like drugs can be up- or down-regulated in the presence of an acute injury and that acute tissue injury enhances the efficacy of peripheral opioids.

Introduction

Clinical and experimental results have shown that the peripheral analgesic efficacy of opioids is enhanced in the presence of inflammation and tissue injury [1,2]. The mechanisms responsible for this phenomenon involve the following events: increases in the opioid receptor mRNA level and opioid receptor expression level [3–5], an increase in the axonal transport and accumulation of these receptors in the peripheral sensory nerve endings [6], and an increase in the opioid agonist binding to their corresponding receptor [7,8]. Moreover, inflammation induces the release of endogenous opioid peptides [1]. Studies investigating the molecular mechanisms involved in the enhanced effects of opioid treatments in the periphery caused by inflammation mainly focus on the µ-opioid receptor and the chronic inflammatory processes [2,5–7,9]. Inflammation enhances the axonal transport of opioid receptors toward the periphery, which is preceded by an increase in opioid receptor mRNA transcription [3,10].

Previously, we demonstrated that crotalphine (CRP), a structural analogue to a novel analgesic peptide that was first identified in the crude venom from the South American rattlesnake Crotalus durissus terrificus [11], induces a potent (0.008–25 µg/kg, p.o.) and long-lasting (2–5 days) anti-nociceptive effect that is mediated by the activation of the peripheral κ-opioid receptor (prostaglandin E2-induced hyperalgesia) and the κ- and δ- (chronic constriction injury of the rat sciatic nerve) opioid receptors [11–13]. The L-arginine-nitric oxide-cGMP pathway is involved in the peripheral anti-nociceptive effect of CRP [13] and opioid agonists [14–17]. The activation of opioid receptors regulates a variety of intracellular signaling cascades, including the PI3K/ß/AKT signaling pathway [18], as well as the activation of mitogen-activated protein kinases (MAPKs) and protein kinase C (PKC) [19–21].

The high efficacy and long-lasting peripheral anti-nociceptive effects of crotalphine have only been observed in the presence of inflammation, and the mechanisms involved in the enhanced effects of CRP in the presence of inflammation are currently unknown. In the present study, we used prostaglandin E2 (PGE2)-induced hyperalgesia in a rat model to characterize the anti-nociceptive effect caused by the peripheral administration of CRP and compared this response with the responses induced by select opioid receptor agonists. Furthermore, we also investigated the
intracellular signaling pathways activated by CRP and the opioid receptor agonists.

**Experimental Procedures**

**Animals**

Male Wistar rats (170–190 g) were used in this study. The animals were housed in a temperature-controlled (21±2°C) and light-controlled (12 h/12 h light/dark cycle) environment. All of the behavioral tests were performed between 9:00 am and 4:00 pm. Standard food and water were available ad libitum. All of the procedures were conducted in accordance with the guidelines for the ethical use of conscious animals in pain research published by the International Association for the Study of Pain [22] and were approved by the Institutional Animal Care Committee of the Butantan Institute (CEUAIB, protocol number 386/2007).

**Drug administration**

The drugs [D-Ala², N-Me-Phe⁴, Gly⁵-ol]-Enkephalin acetate salt (1) (DMGO, 5 µg/paw); [D-Pen²⁵, p-CI-Phe²⁵]-Enkephalin (DPPDE, 20 µg/paw); (−)-trans-[1S,2S]-U-50488 hydrochloride hydrate (U 50,488, 10 µg/paw) [23]; Prostaglandin E₂ (PGE₂, 100 ng/paw) [23,24]; D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr amide (CTOP, 20 µg/paw) [25,26], nor-binaltorphimine dihydrochloride (nor-BNI, 50 µg/paw) [25,27]; N,N-diallyl-Tyr-Alb-Alb-Phe-Leu (IC[174,864,10 µg/paw] [25], methiodine naloxone (1 mg/Kg, subcutaneously) were used in this study [28]. These drugs were purchased from Sigma-Aldrich, Saint Louis, MO, USA. For injection into the rat paw, an aliquot of this stock solution was diluted in sterile saline. The percentage of ethanol in the stock solution was determined as the threshold cycle of the polymerase chain reaction at which the amplified product is first detected. The expression levels were normalized using the cyclofilin expression level as an endogenous reference.

**RNA isolation and cDNA synthesis**

Total RNA was isolated from DRGs and plantar tissue using TRIzol reagent (Gibco Life Technologies, Grand Island, NY, USA). The RNA concentration and integrity were determined, cDNA was synthesized using SuperScript III RNase H-Reverse Transcriptase (Invitrogen Life Technologies, Grand Island, NY, USA). The RNA concentration and integrity were determined, cDNA was synthesized using SuperScript III RNase H-Reverse Transcriptase (Invitrogen Life Technologies, Grand Island, NY, USA) at 42°C for 50 min and real-time polymerase chain reaction was performed. The following primers were used for gene amplification: μ-opioid receptor: sense GCCATCGGTTCT-GCCGTGTAAT; antisense GAGCAGGTTCCTCGAGTAC, κ-opioid receptor: sense GTCAAGAGGCACGTTCGAC, antisense TAGCTCAGTGAAGTACAGTC, δ-opioid receptor: sense ATGGTCAATGGCATGAC, antisense CAGCGA-GATCTTTGGTACAG, Cytofilin: sense 5-AATGCTGGA-CAAAACAAA-3, antisense 5-CCTTTTTCACCCTCC-CAAA-3. The real-time PCR for the opioid receptors and house-keeper gene cytofilin were run separately, and the amplification reactions were performed using the ABI Prism 7700 Sequence Detection System and the SYBR Green PCR Master Mix (Applied Biosystems Life Technologies, Grand Island, NY, USA). The results were quantified as Ct values, where Ct is defined as the threshold cycle of the polymerase chain reaction at which the amplified product is first detected. The expression levels were normalized using the cytofilin expression level as an endogenous reference.

**Immunoblot analysis.** Frozen tissues were homogenized in cold RIPA buffer (1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 10 mg/ml aprotinin, 1 mM sodium orthovanadate in PBS buffer, pH 7.4, 1:300 protease and phosphatase inhibitor cocktail from Sigma-Aldrich, St. Louis, MO, USA (cat. number P8340, P5726, P0044)). The samples were centrifuged at 10,000 × g for 10 min at 4°C. The supernatant was removed and centrifuged again. After centrifugation, the protein concentration in the supernatant was determined using Bradford assay [31]. Aliquots containing 80 µg of total protein were boiled in Laemmli loading buffer (BioRad, Hercules, CA, USA) and then loaded onto a 10% polyacrylamide gel. After separating by electrophoresis, the proteins were transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membranes were blocked in TBST (20 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween 20) containing 5% non-fat dry milk for 1 h at room temperature and then incubated in μ-opioid receptor (C-terminus) rabbit IgG, δ-opioid receptor (C-terminus) rabbit IgG (1:1000, Chemicon, Temecula, CA, USA, cat. numbers AB 3511, AB1560, respectively) or κ-opioid receptor-1 (N-19) goat polyclonal IgG antibody (1:500; Santa Cruz Biototechnology, Dallas, TX, USA, cat. number sc31779) overnight at 4°C. The membranes were then incubated in the appropriate peroxidase-conjugated secondary
antibody (1:5000; anti-rabbit and anti-goat, Sigma-Aldrich, St. Louis, MO, USA, cat. numbers A0545 and A9819, respectively) for 90 min at room temperature and developed using enhanced chemiluminescence (Amersham GE Healthcare Bio-Sciences Corp.; Piscataway, NJ, USA). The signal was detected by autoradiography. Quantification analysis of the blots was performed using the ImageJ software (Scion Corporation based on NIH image). Targeted bands were normalized to GAPDH (1:5000, Advanced ImmunoChemical Inc, Long Beach, CA, USA).

Opioid receptor activation studies: ELISA assay

In vivo studies. Naive and PGE2-sensitized rats were injected with DAMGO (5 μg/paw), DPDPE (20 μg/paw), U 50,488 (10 μg/paw) or CRP (0.6 ng/paw). In the sensitized rats, these drugs were administered 2 h after the PGE2 injection. Approximately 1 h after the CRP or opioid receptor agonist treatment, the animals were perfused through the heart with phosphate-buffered saline and 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB, pH 7.4). The DRG (L5) and plantar tissue were removed, post-fixed for 4 h in 4% PFA, and transferred to a 30% sucrose solution in PB for 48 h to ensure cryoprotection. The tissues were sectioned (14 μm) on a cryostat, and the sections were mounted on histological glass slides covered with silane. Two sections from each region were circled using an ImmEdge PAP pen (Sigma-Aldrich) to form a water-proof barrier, and the resulting well could hold approximately 80 μl of solution. ELISA was performed in these wells using a 1:500 dilution of primary antibody and a 1:500 dilution of secondary antibody. To detect the activated receptor, we used antibodies that are able to distinguish the conformational change in the N-terminus of the opioid receptors following activation [32]. The antibodies were purchased from Proteimax Brazil. The reaction product was transferred to a 96-well plate, and the absorbance at 490 nm was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). 2.4.3.2 Cell culture studies. These studies were performed using cultured DRGs obtained from naive animals. Rats were decapitated, and all of the DRGs (45 ± 50 DRGs) from the cervical, thoracic, lumbar and sacral levels were aseptically removed and collected in Earl’s balanced salt solution (5 mM KCl, 116 mM NaCl, 1 mM NaH2PO4, 8 mM Na2HPO4, 1.46 mM KH2PO4, 8 mM NaHCO3 and 1% glucose). Next, the DRGs were digested in 0.5% collagenase (Sigma, Saint Louis, MO, USA) for 1 min. The resulting pellet was resuspended in DMEM, with 10% inactivated fetal bovine serum (Sigma, Saint Louis, MO, USA) and 1% glucose). The cells were treated with PGE2 (1 μM) for 15 minutes for sensitization. Vehicle was used as a control. Cells were then treated with CRP or opioid receptor agonist (DAMGO, DPDPE or U 50,488 (1 μM) for 15 minutes. In the yoked control wells, only culture medium was added (vehicle treatment). Three separate experiments were conducted on different occasions. For each experiment, new primary cultures were prepared under the same standard experimental conditions. Each treatment was replicated in three different wells. In the pilot studies, we determined the cell viability following the specific concentrations of agonists, CRP and PGE2 used. No significant increase in the number of trypan blue stained cells was observed after these treatments when compared with the vehicle (data not shown). ELISA was performed in each well as previously described.

Intracellular signaling studies. These studies were performed in DRG cell cultures obtained from naive animals. The cells were obtained as previously described (section 2.3.3.2). CRP (1 μM) or U 50,488 (1 μM) was added to the cells untreated or pretreated with PGE2 (1 μM) as previously described. In these studies, Nor-BNI (1 μM) was added to the culture (30 minutes before treatment). After treatment, the cyclic GMP content was measured using a cyclic GMP enzyme immunoassay kit purchased from Amersham Enzymeimmunoassay Biotek (GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA). The phosphorylation of Akt, ERK 1/2 and JNK was evaluated by immunoblot analysis using the previously described method. The DRG cells were homogenized in a lysis buffer as previously described. The cells were incubated in primary antibody, either phosphorylated (p) AKT-T, pERK, pJNK, or non-phosphorylated forms of these proteins (1:1000; Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C and then incubated in HRP-conjugated secondary antibody (1:2000; Amersham Biosciences, Arlington Heights, IL, USA). The blots were visualized using ECL solution for 1 min and exposed onto hyperfilms (Amersham Biosciences, Arlington Heights, IL, USA).

Statistical analysis

The results are presented as the mean ± SEM. For figures 1, Fig. S1–4 the statistical evaluation of data was conducted using a two-way analysis of variance (ANOVA) with post-hoc testing by Tukey. One way ANOVA was used to analyze figures 2, 3, 4, 5, 6, 7, 8, 9, 10, with post-hoc testing by Tukey. A value of P<0.05 was considered significant.

Results

Acute sensitization improves the anti-nociceptive effect of CRP and opioid receptor agonists

The intraplantar injection of CRP (0.6 ng/paw) or the opioid agonists DAMGO (5 μg/paw), U-50488 (10 μg/paw) or DPDPE (20 μg/paw), which were used as positive controls, did not modify the basal nociceptive threshold of naive rats in the rat paw pressure test (Fig. 1A). The intraplantar injection of PGE2 caused a significant decrease in the nociceptive threshold, with a peak response occurring 3 h after the administration (Fig. 1B, checkered bar, and Fig. S1), compared with the basal values obtained before any treatment, which is a characteristic sign of hyperalgesia. The administration of CRP or opioid receptor agonists, in the same doses previously used [11,25], blocked the PGE2-induced hyperalgesia and increased the nociceptive threshold of the animals when compared with the basal values (Fig. 1B). These effects were only observed in the paw injected with CRP or agonists. These treatments did not modify the PGE2-induced hyperalgesia in the contralateral paw (Fig. 1C). In order to confirm the peripheral CRP and opioid agonist effect, rats were treated with naloxone methiodide, a peripherally acting opioid antagonist. This antagonist blocked CRP and opioid agonists-induced anti-
nociception (Fig. S2). In addition, the CRP or opioid receptor agonists systemic injection, in the same doses injected intraplan-
tarly, did not alter PGE2-induced hyperalgesia (Fig. S3). Together, these results indicate that CRP and the opioid receptor agonists, in the doses used in this study, have a local anti-nociceptive effect in the presence of the acute sensitization induced by PGE2.

Previously, we demonstrated that the anti-nociceptive effect of CRP administered orally in this hyperalgesia model is mediated by the activation of the peripheral (local) \( \kappa \)-opioid receptor [11]. To determine whether opioid receptors are involved in the local (intraplantar) anti-nociceptive effect of this peptide, rats were administered selective antagonists of the opioid receptors by i.pl. injection. The anti-nociceptive effect of CRP was abolished in the paw injected with nor-BNI, an antagonist of the \( \kappa \)-opioid receptors (Fig. 1B), but not by CTOP or ICI 174,864, \( \mu \)- and \( \delta \)-opioid receptor antagonists, respectively (Fig. 1B). These results indicate that the peripheral anti-nociceptive effect of CRP is mediated by the activation of the peripheral \( \kappa \)-opioid receptor. The opioid receptor antagonists CTOP, ICI 174,864, and Nor-BNI blocked the anti-nociceptive effects induced by their corresponding agonist (DAMGO, DPDPE, and U 50,488, respectively), which confirms the efficacy of the antagonist doses used (Fig. 1B). The antagonists, per se, had no effect on the hyperalgesia induced by PGE2 (data not shown).

### Acute sensitization interferes with the opioid receptor levels

To elucidate the potential mechanisms involved in the anti-nociceptive effect of CRP and the opioid agonists observed in the presence of prostaglandin E2 sensitization, we investigated whether this eicosanoid treatment alters the mRNA expression levels of the opioid receptors. PGE2 treatment significantly increased the mRNA expression levels of the \( \mu \)- and \( \kappa \)-opioid receptors in the ipsilateral (2.5- and 3.6-fold, respectively) and contralateral (0.8- and 2-fold, respectively) DRGs compared with the DRGs obtained from naïve animals (Figs. 2A, 2B). An increase in the mRNA expression level of the \( \delta \) opioid receptor was only detected in the ipsilateral DRGs (3.7-fold) (Fig. 2C).

To determine whether the changes in the mRNA levels resulted in changes in the opioid receptor protein expression levels, we
performed immunoblot assays using the DRGs and plantar tissue. The intraplantar injection of PGE2 increased the μ- and κ-opioid receptor protein expression levels in the ipsilateral DRGs (79% and 168%, respectively) and the plantar tissue (43% and 75%, respectively) compared with the tissues obtained from naïve animals (Figs 3A and B). In contrast, a 30% decrease in the δ-opioid receptor protein expression level was detected in the plantar tissue from the PGE2 injected animals (Fig. 3C). Despite the changes detected in the ipsilateral DRGs mRNA levels, no PGE2-related changes in the μ-, κ-, and δ-opioid receptor protein expression levels were detected in the contralateral DRGs (Fig. 3). PGE2-induced hyperalgesia was confirmed in all animals used for mRNA and immunoblot (Fig. S4).

PGE2 sensitization enhances the CRP and agonist-mediated opioid receptor activation

It has been well established that GPCRs undergo conformational changes in the N-terminus following receptor activation [32]. To determine whether PGE2 activates opioid receptors, we performed an ELISA assay (in plantar tissue and DRG slices) using conformation state-sensitive antibodies that recognize activated opioid receptors according to the methods published by Gupta et al. (2007). To determine the total expression level of the opioid receptors, the same antibodies used for the immunoblot assays were also used in these assays.

Consistent with the immunoblot assay results, the intraplantar injection of PGE2 increased the expression levels of the μ- and κ-opioid receptors in the plantar tissue (43% and 72%, respectively) (Fig. 4A) and the DRG (43% and 97%, respectively) (Fig. 4B) and decreased the expression level of the δ opioid receptor in the plantar tissue (30%). No changes in opioid receptor activation, however, were detected using the conformation state-sensitive antibodies compared with the levels observed in the tissues from naïve animals. This result indicates that PGE2 does not activate opioid receptors.

Because PGE2 altered the expression profiles of the opioid receptors without altering their activation, we investigated whether CRP or opioid receptor agonists increase the activation of the opioid receptors in PGE2-sensitized plantar tissue. The results show that the intraplantar injection of DAMGO (5 μg/paw), U 50,488 (10 μg/paw) and DPDPE (20 μg/paw) into naïve animals results in conformational changes in the μ-, κ- or δ-opioid receptors, respectively, when compared with the untreated rats (Fig. 5A). Interestingly, CRP (0.6 ng/paw) caused κ- but not μ- or δ-opioid receptor activation (Fig. 5B). These results indicate that these opioid receptors have been activated and confirm the involvement of the κ-opioid receptor in the CRP-mediated antinociceptive effect. The intraplantar injection of PGE2 increases the opioid receptor activation caused by CRP and the μ- and κ-opioid receptor agonists (32%, 42% and 36%, respectively) compared with the values obtained without sensitization (Figs. 5A, 5B). In contrast, PGE2 inhibited the activation of the δ-opioid receptor compared with the values obtained from the tissues collected from the animals that were only treated with the δ-opioid agonist. Our results suggest that acute sensitization increases the activation of the opioid receptors by CRP and, depending on the type of opioid receptor, by selective agonists.

To confirm our in vivo findings, the effect of CRP and opioid receptor agonists on opioid receptor activation was evaluated using primary neuron cultures isolated from the DRGs of adult naïve rats. CRP added to the cell culture medium did not result in conformational changes in the μ-, δ- or κ-opioid receptors compared with the naïve controls (Fig. 6A). Conversely, treating PGE2-sensitized DRG cells with CRP this peptide now induces conformational changes in the κ-opioid receptor but not in the μ- or δ-opioid receptors when compared with the cells treated with CRP but not PGE2 (Fig. 6A). These results indicate that PGE2 triggers the CRP activation of the κ-opioid receptor. Incubating the DRG cells in the opioid receptor agonists DAMGO, U 50,488 and DPDPE resulted in the activation of their corresponding μ-, κ-, and δ-opioid receptors (70%, 72% and 143%, respectively, Fig. 6B). The activation of the μ- and κ-opioid receptors increased significantly when the cells were pretreated with PGE2. Interestingly, pretreating the DRG neurons with PGE2 inhibited the DPDPE activation of the δ-opioid receptor compared with the cells treated with the agonist alone (Fig. 6B).
PGE2 sensitization enhances the CRP-mediated κ-opioid receptor intracellular signaling

Effect on cyclic GMP level. Because the anti-nociceptive effect of CRP is mediated by the L-arginine-nitric oxide-cGMP pathway [12], we investigated the effect of CRP on the cyclic GMP (cGMP) level in DRG cell cultures. CRP (1 μM) increased the cGMP level compared with the control cells (Fig. 7), and pretreating the cells with PGE2 (1 μM) significantly increased (30%) the CRP-induced cGMP release. Nor-BNI, a κ-opioid receptor antagonist, blocked this effect. The κ-opioid receptor agonist U 50,488 (1 μM) was used as a positive control and increased the cyclic nucleotide level. Pretreating the cells with PGE2 further increased (33%) the cyclic nucleotide level compared with the cells that were treated with only the agonist (Fig. 7).

Effect on AKT activation. AKT phosphorylation is involved in the peripheral anti-nociceptive effect of opioids, such as morphine and U 50,488 [18,33]. Therefore, we evaluated whether CRP increases AKT phosphorylation in PGE2-sensitized cells. Treating DRG cells with PGE2 (1 μM) increased the AKT phosphorylation level compared with the saline-treated (control) cells (Fig. 8), and CRP (1 μM) did not interfere with AKT phosphorylation compared with the control cells and the PGE2-treated cells (Fig. 8). The κ-opioid receptor agonist U 50,488 (1 μM) was used as a positive control and activated AKT (Fig. 8).

Effect on MAPK activation. The activation of the κ-opioid receptor increases the phosphorylation of MAPKs (ERK1/2 and JNK) in neuronal and non-neuronal cells [34]. Therefore, MAPK phosphorylation may be a useful indicator of opioid receptor activation in DRG cells. CRP increased ERK1/2 phosphorylation in DRG cells (Fig. 9A), and pretreating the cells with PGE2 significantly increased (1.5-fold) the CRP-mediated ERK1/2 phosphorylation (Fig. 9A). PGE2 alone, however, does not appear to induce ERK1/2 phosphorylation. The κ-opioid receptor antagonist Nor-BNI inhibited the CRP-mediated ERK1/2 phosphorylation, which suggests that the κ-opioid receptor is involved in this process. Nor-BNI alone does not appear to cause ERK1/2 phosphorylation. Based on these results, we further evaluated the

Figure 3. Intraplantar injection effect of prostaglandin E2 (PGE2) on protein expression of μ (A), κ (B) and δ (C) opioid receptors. The changes in protein levels of opioid receptors were determined by immunoblotting, in dorsal root ganglia (DRG) and plantar tissue obtained 3 h after PGE2 injection (100 ng/paw). Data are presented as mean ± SEM and expressed as % of control (naïve) animals. *Significantly different from mean values of naïve animals, n=6 per group (p<0.05). Data were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing by Tukey. doi:10.1371/journal.pone.0090576.g003
effect of the κ-opioid receptor agonist U 50,488 on ERK1/2 activation. Treating neurons with U 50,488 increased the level of phosphorylated ERK1/2, and the phosphorylated ERK1/2 level was further increased in cells that were pretreated with PGE2 (Fig. 9A). Treating neurons with either CRP or U 50, 488 also induced JNK phosphorylation (9- and 2.5-fold, respectively). Similar to the ERK1/2 expression profile, pretreating the cells with PGE2 increased the CRP- and U 50, 488-mediated JNK phosphorylation (10.5- and 3.5-fold, respectively). PGE2 alone does not appear to induce JNK phosphorylation. Nor-BNI did not interfere with this CRP effect, but this antagonist did increase the level of phosphorylated JNK (13-fold) (Fig. 9B).

PKCζ is involved in CRP-induced MAPK activation. Because CRP appears to activate ERK and JNK, we further investigated the potential mechanisms involved in this effect. Previous studies indicate that PKCζ is involved in the activation of ERK1/2 by the κ-opioid receptor agonist [20]. To examine the direct role that PKCζ plays in the activation of the MAPKs by CRP, we used the PKCζ pseudosubstrate, which selectively inhibits the atypical PKCζ isoform [35]. Pretreating the DRG cells with the PKCζ pseudosubstrate abolished the CRP-mediated ERK1/2 phosphorylation in both the PGE2-sensitized and unsensitized cells (Fig. 10A). In contrast, the ζ pseudosubstrate did not affect the CRP-mediated JNK phosphorylation but did inhibit the increase in CRP-induced JNK phosphorylation observed in the presence of PGE2 (Fig. 10B). The TAT carrier was used as a negative control.

Discussion

We previously reported that CRP, a 14-aminoacid peptide isolated from C. d. terrificus venom, has a potent, long-lasting and peripheral opioid receptor-mediated anti-nociceptive effect [11–13]. In this study, we demonstrated that the potency and long-lasting anti-nociceptive effect of CRP depends on tissue inflammation. It has been well established that the local efficacy of opioid drugs is enhanced in the presence of tissue injury/inflammation, but the mechanisms involved in this phenomenon remain under investigation [6,7,9]. In the present study, we also elucidated some of the mechanisms involved in the increased peripheral anti-nociceptive efficacy of CRP and opioid receptor agonists in the

Figure 4. PGE2, per se, does not activate opioid receptors. The plantar tissue (A) and dorsal root ganglia (ipsi and contralateral) (B) were obtained 3 h after PGE2 injection (100 ng/paw). Tissues obtained from naïve animals were used as controls. The tissues were sectioned and probed with anti-μ, κ or δ antibodies. (A) The black bar represents the results obtained with the conformation state-sensitive antibodies whereas the white bar represents the results obtained using the control antibodies (western blotting assay antibodies). (B) The first couple of bars represents the results obtained using the control antibodies (western blotting assay antibodies). The second one represents the conformation state-sensitive antibodies. The dotted line represents the values obtained for naïve animals. * Significantly different from mean values of naïve animals (p<0.05). Data were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

doi:10.1371/journal.pone.0090576.g004
presence of hyperalgesia. We observed the following results: (a) the local intraplantar (i.pl.) injection of a low dose of CRP or selective opioid receptor agonists, which are ineffective at increasing the nociceptive threshold in naïve animals in the rat paw pressure test naïve, produced anti-nociception in a PGE2-induced hyperalgesia model. The agonists, CRP, or vehicle (control) were administered 2 h after PGE2 injection. ELISA assay was performed in slices of plantar tissue, using conformation state-sensitive antibodies (μ, κ, δ activated). Tissues were collected 3 h after PGE2 injection. *Significantly different from mean values of control animals (dotted line), n = 6 animals per group (p < 0.05). #Significantly different from mean values of CRP or agonist alone (p < 0.05). Data were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

doi:10.1371/journal.pone.0090576.g005

In our study, we first evaluated the effect of an intraplantar (i.pl.) injection of CRP or selective opioid receptor agonists on the nociceptive threshold in naïve animals in the rat paw pressure test naïve, produced anti-nociception in a PGE2-induced hyperalgesia model. In this hyperalgesia rat model, the CRP effect was mediated by activation of the κ-opioid receptor. (b) The i.pl. administration of PGE2 increased the peripheral mRNA expression levels of the μ-, δ-, and κ-opioid receptors and the peripheral protein expression levels of the μ- and κ-opioid receptors within 3 h of the injection. The eicosanoid also increased the activation of the μ- and κ-opioid receptors by their corresponding agonist. In contrast, the PGE2 treatment decreased the δ-opioid receptor protein level and activation of the δ-opioid receptor by its agonist. (c) In cultured DRG neurons, the activation of specific intracellular signaling pathways (MAPKs and PKCζ) by CRP was enhanced following PGE2 sensitization. The results presented here provide evidence that tissue injury regulates the expression of peripheral opioid receptors and their activation by CRP and selective opioid receptor agonists and that tissue injury also contribute to activation of specific intracellular signaling pathways.

Figure 5. PGE2 improves agonist-mediated opioid receptor activation. Naïve or prostaglandin E2 (PGE2, 100 ng/paw) injected rats were treated with DAMGO (5 μg/paw), U50,488 (10 μg/paw), DPDPE (20 μg/paw), (Panel A) or crotalpine (CRP, 0.6 ng/paw) (Panel B). The agonists, CRP, or vehicle (control) were administered 2 h after PGE2 injection. ELISA assay was performed in slices of plantar tissue, using conformation state-sensitive antibodies (μ, κ, δ activated). Tissues were collected 3 h after PGE2 injection. *Significantly different from mean values of control animals (dotted line), n = 6 animals per group (p < 0.05). #Significantly different from mean values of CRP or agonist alone (p < 0.05). Data were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

doi:10.1371/journal.pone.0090576.g005

Figure 6. PGE2 improves agonist-mediated opioid receptor activation in primary neuronal cell culture. Cells from dorsal root ganglia were obtained from naïve rats and incubated at 37 °C, in a 5% of CO2 for two days. On the third day, the cells were incubated with PGE2 (1 μM) or vehicle for 15 min and further incubated with 1 μM of crotalpine (CRP, A) or DAMGO, U50,488, DPDPE (B) for 15 min. ELISA assay was performed directly on fixed cells, using conformation state-sensitive antibodies (activated). Three separate experiments were carried out on different occasions.* Significantly different from mean values of naïve animals (dotted line) (p < 0.05), # Significantly different from mean values of CRP or agonist alone, average of 3 independent experiments (p < 0.05). Data were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

doi:10.1371/journal.pone.0090576.g006
agonists and CRP effects were reversed by naloxone methiodide, a peripherally acting opioid antagonist. Additionally, the drug’s effect seems to be restricted to the receptors in the injury site, because a systemic subcutaneous injection of the equivalent dose of drugs used intraplantarly did not induced anti-nociception. We also demonstrate that the effect of CRP was inhibited by the i.pl. injection of the k-opioid receptor antagonist but that it was unaffected by the injection of the µ- or δ-opioid receptor antagonists. These results are consistent with our previous results showing that the effect of CRP administered orally is mediated by the k-opioid receptor in acute pain models [11]. The efficacy of the opioid receptor antagonist doses used was confirmed by the results showing that the i.pl. injection of the antagonists blocked the peripheral anti-nociceptive effect of their corresponding agonist.

Taken together, these results provide evidence that the local anti-nociceptive effects of CRP and opioids depend on previous sensitization. These findings are consistent with the clinical and experimental observations reporting that opioids are more potent under inflammatory conditions [4,5,39–42]. The mechanisms involved in this phenomenon have not been fully elucidated, but biochemical assay studies have shown that inflammation/tissue injury enhances the axonal transport of opioid receptors toward the periphery, which is preceded by an increase in the opioid receptor mRNA transcription level [3,10]. Importantly, peripheral opioid receptor levels do not increase during the early stages of the inflammatory process, but these levels do increase at later stages of the inflammation [43,44]. Based on these findings and the lack of experimental data showing the effect of PGE2 on the opioid receptor expression levels, we next investigated whether this eicosanoid affects the expression levels of the opioid receptors. Our results indicate that PGE2 sensitization increases the mRNA and protein expression levels of the µ- and k-opioid receptors in the dorsal root ganglia and plantar tissue of rats. Interestingly, PGE2 appears to increase the δ-opioid receptor mRNA expression level in the DRGs while simultaneously PGE2 decreasing the δ-opioid receptor protein level in the paw. This discrepancy may be a consequence of protein degradation during axonal transport. Further studies, however, are needed to investigate these differences. Furthermore, despite an increase in the δ-opioid mRNA expression level in the DRGs, the protein level remained unchanged in this tissue. An evaluation of the protein expression level at later time points may explain whether this discrepancy is a time point issue. Studies have shown that inflammatory substances, such as Freund’s complete adjuvant (FCA) and carrageenan, increase the mRNA and protein expression levels of the µ-opioid receptor in the DRGs within 1 h after treatment [3,6]. These discrepancies suggest that µ- and δ-opioid receptor require different timing to be up or down regulated during inflammation. We further examined whether PGE2 induces opioid receptor

Figure 7. Effect of crotalphine on cyclic GMP levels in primary culture of DRG cells. Cells from DRG were obtained from naïve rats and incubated at 37 °C in a 5% of CO2 for two days. On the third day, the cells were incubated with Nor-BNI (1 mM) or vehicle (saline - Sal) for 15 min, and further incubated with 1 µM of crotalphine (CRP), U50,488, or saline, for 15 min. Cells were lysed and subjected to enzyme immunoassay. *Significantly different from mean values of control cells (p<0.05), #Significantly different from mean values of CRP alone (p<0.05), Significantly different from mean values of U 50,488 alone (p<0.05). cGMP levels were analysed by one-way analysis of variance with a post-hoc Tukey test. Data were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing by Tukey. doi:10.1371/journal.pone.0090576.g007

Figure 8. Effect of crotalphine (CRP) on AKT phosphorylation in primary culture of DRG cells. Cells from DRG were obtained from naïve rats and incubated at 37 °C in a 5% of CO2, for two days. On the third day, the cells were incubated with PGE2 (1 µM) or vehicle (saline - Sal) for 15 min. and further incubated with 1 µM of CRP, U50,488, or saline, for 15 min. Cells were scrapped and homogenized, and the total homogenate was subjected to western blotting. (A) The ratio of phospho-protein to total protein is expressed as percentage from control (Sal=Sal). Three separate experiments were carried out on different occasions. *Significantly different from mean values of control cells (p<0.05). AKT levels were analysed by one-way analysis of variance with a post-hoc Tukey test. (B) Representative blots showing the levels AKT in the total listate of DRGs. doi:10.1371/journal.pone.0090576.g008
activation by performing ELISA using plantar tissue slice preparation and conformation state-sensitive antibodies specific to activated opioid receptors (the N-terminal region of GRPCs undergo a conformational change following receptor activation that can be selectively detected by these specific antibodies [32,45,46]). Our results show that PGE2 did not alter the activation state of these receptors, though the opioid receptor expression levels increased.

Next, we determined whether sensitization by this eicosanoid improves the agonist-mediated receptor activation. Using the state-sensitive antibodies we detected a higher level of μ- and κ-opioid receptor activation by their corresponding agonists in PGE2-sensitized cells.

Pretreating the cells with PGE2 inhibited δ-opioid receptor activation by its agonist. This result could be the consequence of the PGE2-mediated δ-opioid receptor down-regulation. Zollner et al. (2003) showed that despite increasing the number of μ-opioid receptor binding sites on the DRG cell membrane, the intraplantar injection of FCA does not affect the affinity of the full and partial μ-opioid agonists in rats [7]. Furthermore, one important finding from their study is that there was a significant increase in the DAMGO-stimulated G-protein activation in FCA-treated animals.

The results from the present study demonstrate that CRP treatment is sufficient for activation of the κ-opioid receptor in the presence of PGE2. CRP, however, may not directly activate opioid receptors [11]. Another study showed that the anti-nociceptive effect of CRP can be reversed by dynorphin A anti-serum, which indicates that endogenous opioids are involved in this phenomenon (Machado et al., in press). We still cannot dismiss, however, that CRP may have a direct effect on opioid receptors. Nevertheless, the involvement of an opioid mechanism in the CRP anti-nociceptive effect is supported by the results obtained in this study and in previous studies [11–13].

Based on our in vivo findings, we next wanted to determine the effect of CRP on opioid receptor activation in PGE2-sensitized DRG cells isolated from naïve animals. PGE2 increased the CRP-mediated κ-opioid receptor activation. This result is consistent with our in vivo result showing that the CRP anti-nociceptive effect in the PGE2-induced hyperalgesia model is mediated by κ-opioid receptor activation.

Because inflammation increases the frequency of interactions between opioid receptors and G proteins and activates specific intracellular signaling pathways [7,47], we decided to investigate the molecular pathways activated by CRP in the presence or absence of PGE2 sensitization. It has been shown that the opioid receptor-mediated anti-nociceptive effect is regulated by the cGMP, AKT, and MAPK signaling pathways [20,48–50]. Furthermore, we recently showed that cGMP is involved in the CRP anti-nociceptive effect [12]. In the present study, we demonstrated that CRP increases the cGMP level and that this effect is enhanced by PGE2. AKT activation is also involved in the peripheral anti-nociception induced by opioids, such as morphine and U 50,488 [18,33]. Our cell culture results indicate that the κ-

---

**Figure 9. Effect of crotalphine (CRP) on phosphorylated form of ERK (A) and JNK (B) in primary culture of DRG cells.** Cells from DRG were obtained from naïve rats and incubated at 37°C in a 5% of CO₂ for two days. On the third day, cells were incubated with Nor-BNI (1 μM) for 30 min and PGE₂ (1 μM) or vehicle (saline - Sal) for 15 min and further incubated with 1 μM of CRP, US0.488, or saline, for 15 min. Cells were scraped and homogenized, and the total homogenate was subjected to western blotting. The ratio of phospho-protein to total protein is expressed as % of control (sal+s). GAPDH was used as the internal loading control. Three separate experiments were carried out on different occasions.*Significantly different from mean values of control cells (p<0.05). (A) p-ERK1/2 and (B) p-JNK levels were analysed by one-way analysis of variance with a post-hoc Tukey test. Representative blots showing the levels p-ERK1/2 and p-JNK in the total lysate of DRGs. # Significantly different from mean values of CRP alone (p<0.05).

doi:10.1371/journal.pone.0090576.g009
opioid receptor agonist (U 50,488), used as a positive control, and not CRP, phosphorylates AKT. Interestingly, recent findings obtained by our group indicate that the PI3-AKT signaling pathway is not involved in the CRP anti-nociceptive effect in the PGE2-induced hyperalgesia model (Pedroso and Cury, unpublished data). CRP and the κ-opioid receptor agonist activated ERK1/2 and JNK. It is important to mention that in all of the experiments, PGE2 increased the phosphorylation levels of MAPK caused by CRP. The role that MAPKs play in the CRP-mediated anti-nociceptive effect is currently unknown. It is possible that the activation of these kinases support the expression of the receptors/channels and/or transcriptional factors involved in anti-nociception [51–54]. For example, the phosphorylation of MAPK activates transcription factors, such as CREB, which regulates dynorphin gene expression [53,55]. Our results are consistent with the previously reported results showing that the κ-opioid receptor agonist U 50,488 activates MAPKs, such as ERK1/2 and p38 MAPK [20,50]. Furthermore, we propose that the effect of CRP on ERK phosphorylation is mediated by activation of the κ-opioid receptor because the selective opioid receptor antagonist Nor-BNI blocked this effect. We also found that Nor-BNI activates the JNK pathway. These results are consistent with previous results showing that Nor-BNI increases the level of phospho-JNK in the HEK293 cell line [56]. It has been well established that the pharmacological effects of Nor-BNI, such as the antagonistic effect on agonist-induced anti-nociception and intracellular signaling, are long lasting [56,57] and involve an interaction between κ-opioid receptors and JNK phosphorylation [56]. Therefore, the JNK pathway may play an important role in κ-opioid interacting substrates and may contribute to the long lasting activity of CRP[11].

Based on the results showing that CRP induces the phosphorylation of MAPKs and considering that protein kinase C (PKC) is involved in numerous intracellular signaling pathways in several cellular models [58], we next investigated the role of PKC in CRP-mediated signaling. A previous study by Belcheva et al. (2005) using cultured astrocytes, showed that PKCζ is involved in the activation of MAPKs by opioid agonists [20]. To examine the role of PKCζ in the activation of MAPKs by CRP, we used the PKCζ pseudosubstrate, which selectively inhibits the atypical ζ- and λ-PKC isozymes [35]. Because PKCλ is not expressed in DRGs, the ζ pseudosubstrate should only selectively inhibit PKCζ in these cells. Our results show that PKCζ activation is involved in the CRP-induced increase in phospho-ERK1/2 and JNK in cultured DRG cells; treating these cells with the ζ pseudosubstrate blocked the activation of these kinases by CRP. These results are consistent with the results obtained by Belcheva et al. (2005) [20] that showed U 69,593, a κ-opioid receptor agonist, stimulates the activation of MAPKs via PKCζ.

Figure 10. Involvement of PKCζ on crotalphine-mediated ERK1/2 and JNK phosphorylation in DRG primary culture. Cells from DRG were obtained from naïve rats and incubated at 37 °C in a 5% of CO2 for two days. On the third day, cells were incubated for 30 minutes with TAT carrier (control) or ζ pseudosubstrate (1 μM) followed by incubation with PGE2 or vehicle (15 minutes). The neurons were then incubated with 1 μM of crotalphine (CRP) and TAT or ζ pseudosubstrate for 15 minutes. Cells were scrapped and homogenized, and the total homogenate was subjected to western blotting for (A) pERK1/2 and (B) pJNK. The ratio of phospho-protein to total protein is expressed as % of control (Sal+Sal). GAPDH was used as the internal loading control. Three separate experiments were carried out on different occasions.*Significantly different from mean values of control cells (p<0.05). # Significantly different from mean values of CRP alone (p<0.05). p-ERK1/2 and p-JNK levels were analysed by one-way analysis of variance with a post-hoc Tukey test. Representative blots showing the levels pERK1/2 or pJNK in the total lysate of DRGs.
doi:10.1371/journal.pone.0090576.g010
In conclusion, we propose that CRP has a more potent peripheral anti-nociceptive effect under conditions of acute sensitization. The mechanisms responsible for this phenomenon involve increased expression levels and the activation of opioid receptors as well as increases in the cGMP levels, the phosphorylation of MAPKs and the activation of PKCζ in the periphery. These results further elucidate the important peripheral molecular mechanisms involved in pain control and identify interesting therapeutic alternatives for inducing peripheral analgesia.

Supporting Information

Figure S1 Time-course for intraplantar injection of prostaglandin E2 (PGE2) in the rat nociceptive threshold. Pain threshold was obtained in the rat paw pressure test, before (time 0) and 1, 3, 5 and 8 h after intraplantar injection of PGE2 (100 ng/paw) or saline (control). Data represent mean values ± S.E.M. for six rats per group. * significantly different from baseline, # significantly different from control. Data were analyzed by two-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

(TIF)

Figure S2 Effect of methiodide naloxone (MN) on the local crotaphine (CRP) and opioid receptor agonists-induced anti-nociception. Pain threshold was obtained in the rat paw pressure test, before (dotted line) and 3 h after intraplantar injection of PGE2 (100 ng/paw), CRP (0.6 ng/paw), DAMGO (μ opioid receptor agonist, 5 μg/paw), DPDPF (δ opioid receptor agonist, 20 μg/paw), U-50488 (κ opioid receptor agonist, 10 μg/paw) were injected 2 h after PGE2 administration. NM (1 mg/Kg), were injected by the subcutaneous route 15 minutes before the nociceptive threshold assessment. Data represent mean values ± S.E.M. for five rats per group. * significantly different from baseline (dotted line), # significantly different from control (saline = SAL). Data were analyzed by two-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

(TIF)

Figure S3 Comparative effect between systemic and local injection of crotaphine (CRP) and opioid receptor agonists. Pain threshold was obtained in the rat paw pressure test, before (dotted line) and 3 h after intraplantar injection of PGE2 (100 ng/paw). CRP (0.6 ng), DAMGO (μ opioid receptor agonist, 5 μg), DPDPF (δ opioid receptor agonist, 20 μg), U-50488 (κ opioid receptor agonist, 10 μg) were injected by subcutaneous (systemic) or intraplantar (local) route, 2 h after PGE2 administration. Data represent mean values ± S.E.M. for five rats per group. * significantly different from baseline (dotted line), # significantly different from control (saline = SAL). Data were analyzed by two-way analysis of variance (ANOVA) with post-hoc testing by Tukey.

(TIF)

Acknowledgments

We thank Juliana Sousa de Carvalho and Marie-Helen Disatnik for technical assistance and Andrea S. Heimann from Proteinmax Biotechnology for critical suggestions with experiments involving the conformation state-sensitive antibodies.

Author Contributions

Conceived and designed the experiments: VOZ YC. Performed the experiments: VOZ VPG ACOF. Analyzed the data: VOZ YC. Contributed reagents/materials/analysis tools: VOZ JCBF CAP DMR YC. Wrote the paper: VOZ YC.

References

1. Stein C (1993) Peripheral mechanisms of opioid analgesia. Anesth Analg 76: 192–199.
2. Obara I, Parkina JR, Korostynski M, Makoch W, Kaminska D, et al. (2009) Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain 141: 283–291.
3. Pacler W, Zollner C, Brack A, Shaqura MA, Krause H, et al. (2004) Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. Neuroscience 129: 473–479.
4. Markawa K, Minami M, Masuda T, Sato H (1996) Expression of mu- and kappa-opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Pain 65: 365–371.
5. Cahill CM, Morinville A, Hoffert C, O’Donnell D, Beaudet A (2003) Upregulation of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammation. J Pharmacol Exp Ther 308: 712–718.
6. Shaqura MA, Zollner C, Mousa SA, Stein C, Schafer M (2004) Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammation. J Pharmacol Exp Ther 308: 712–718.
7. Antonijevic I, Mousa SA, Schafer M, Stein C (1995) Perineural defect and peripheral opioid analgesia in inflammation. J Neurosci 15: 163–172.
8. Shaqura MA, Zollner C, Mousa SA, Stein C, Schafer M (2004) Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammation. J Pharmacol Exp Ther 308: 712–718.
9. Antonicjievic I, Mousa SA, Schafer M, Stein C (1995) Perineural defect and peripheral opioid analgesia in inflammation. J Neurosci 15: 163–172.
AKT/nNOS/NO/KATP signaling pathway. Proc Natl Acad Sci U S A 107: 4442–4447.

19. Law BK, Walten-Law ME, Emtihaj AJ, Chylil A, Aakre ME, et al. (2000) Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem 275: 38262–38267.

20. Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, et al. (2005) Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 280: 27662–27669.

21. Connor M, Christie MD (1999) Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 26: 495–499.

22. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109–110.

23. Picolo G, Giorgi R, Bernardi MM, Cury Y (1998) The antinociceptive effect of Crotalus durissus terrificus snake venom is mainly due to a supraspinally integrated response. Toxicon 36: 223–227.

24. Segond von Banchet G, Scholze A, Schahle HG (2003) Prostaglandin E2 increases the expression of the neurokinin 1 receptor in adult sensory neurones in culture: a novel role of prostaglandins. Br J Pharmacol 139: 672–680.

25. Picolo G, Giorgi R, Cury Y (2000) delta-opioid receptors and nitric oxide mediate the analgésic effect of Crotalus durissus terrificus snake venom. Eur J Pharmacol 391: 53–62.

26. Gendron L, Pintar JE, Chavkin C (2004) Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a delta- and kappa-opioid receptor agonist. Life Sci 75: 559–573.

27. Randall LO, Selino JF (1957) A method for measurement of analgesia activity on injured tissue. Arch Inst Pharmacodyn 111: 209–219.

28. Bradford MS (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.

29. Gupta A, Decailiot FM, Gomes I, Tkalych O, Heimann AS, et al. (2006) Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell 124: 437–446.

30. Bruchas MR, Chavkin C (2007) Essential role of mu opioid receptor in systemic and at the site of inflammation against capsaicin-induced pain. J Neurochem 105: 201–209.

31. Connor M, Christie MD (1999) Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 26: 495–499.

32. Gupta A, Decailiot FM, Gomes I, Tkalych O, Heimann AS, et al. (2006) Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell 124: 437–446.

33. Cunha TM, Souza GR, Domingues AC, Carreira EU, Lotufo CM, et al. (2004) Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a delta- and kappa-opioid receptor agonist. Life Sci 75: 559–573.

34. Bruchas MR, Macey TA, Lowe JD, Chavkin C (2006) Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281: 14001–14009.

35. Swatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14: 311–317.

36. Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5: 173–183.

37. Carlezon WA, Jr., Duman RS, Nestler EJ (2005) The many faces of CREB. Nat Rev Neurosci 5: 173–183.

38. Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14: 311–317.

39. Stein C, Millan MJ, Shippenberg TS, Peter K, Heiz A (1989) Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 248: 1269–1275.

40. Mousa SA, Machelska H, Schafer M, Stein C (2002) Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. J Neuroimmunol 126: 5–15.

41. Furst S, Riba P, Friedrich T, Timar J, Al-Khrasani M, et al. (2005) Peripheral versus central antinociceptive actions of 6-amino-acid-substituted derivatives of 14-O-methylmorphine in acute and inflammatory pain in the rat. J Pharmacol Exp Ther 312: 609–618.

42. Nunez S, Lee JS, Zhang Y, Bai G, Ro JY (2007) Role of peripheral mu-opioid receptors in inflammatory orofacial muscle pain. Neuroscience 146: 1346–1354.

43. Schafer M, Immay Y, Uhl GR, Stein C (1995) Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia. Eur J Pharmacol 279: 163–169.

44. Zhou L, Zhang Q, Stein C, Schafer M (1998) Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia. J Pharmacol Exp Ther 286: 1000–1008.

45. Lecat S, Buchar B, Mely Y, Galzi J (2002) Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish CAMP signaling but preserve intracellular calcium responses. J Biol Chem 277: 42043–42048.

46. Decailiot FM, Befort K, Filiol D, Yue S, Walker P, et al. (2005) Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat Struct Biol 10: 629–636.

47. Selley DE, Berivogel CS, Childers SR (1993) Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins. Mol Pharmacol 44: 731–741.

48. Belcheva MM, Vogel Z, Ignatova E, Avidor-Reiss T, Zippel R, et al. (1998) Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem 70: 635–645.

49. Bohm LN, Belcheva MM, Coscia CJ (2000) Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem 74: 364–373.

50. Bruchas MR, Macey TA, Lowe JD, Chavkin C (2006) Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281: 18001–18009.

51. Carlezon WA, Jr., Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28: 436–445.

52. Bruchas MR, Xu M, Chavkin C (2008) Repeated swim stress mediates activation of extracellular signal-regulated kinase 1/2. Neuronreport 19: 1417–1422.

53. Kreibich AS, Bensky LA (2004) cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci 24: 6686–6692.

54. Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, et al. (2007) Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282: 29903–29911.

55. Melfi EF, Mityatek M, Bruchas MR, Chavkin C (2010) Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 107: 11608–11613.

56. Velizquez KT, Mohammad H, Switzer SM (2007) Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res 55: 578–589.